Linked Life Data

17588546

Source:http://linkedlifedata.com/resource/pubmed/id/17588546

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2007-11-13
pubmed:abstractText
Recent studies suggest that the treatment of major depressive disorder (MDD) with newer antidepressant drugs that simultaneously enhance norepinephrine and serotonin neurotransmission might result in higher response and remission rates than the selective serotonin reuptake inhibitors (SSRIs). The goal of our work was to compare response rates among patients with MDD treated with either of these two broad categories of antidepressant drugs.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0006-3223
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
62
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1217-27
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
pubmed:affiliation
Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, MA 02114, USA. gpapakostas@partners.org
pubmed:publicationType
Journal Article, Comparative Study, Review, Meta-Analysis, Research Support, N.I.H., Extramural